Last reviewed · How we verify

VIAject™

Biodel · Phase 3 active Small molecule

VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action.

VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameVIAject™
SponsorBiodel
Drug classRapid-acting insulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

VIAject combines human insulin with a patented diluent containing an excipient (likely citrate or similar) that enhances subcutaneous absorption kinetics, allowing faster peak insulin levels and shorter time-to-action compared to conventional insulin formulations. This rapid onset is intended to better match postprandial glucose excursions in diabetic patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results